


 Cite this: *RSC Adv.*, 2021, 11, 29661

# Chlorinated metabolites with antibacterial activities from a deep-sea-derived *Spiromastix* fungus†

 Siwen Niu,<sup>ab</sup> Dong Liu,<sup>a</sup> Zongze Shao,<sup>b</sup> Jiang Huang,<sup>id</sup><sup>a</sup> Aili Fan<sup>a</sup> and Wenhan Lin<sup>id</sup><sup>\*ac</sup>

Chromatographic separation of the solid cultures of a deep-sea-derived *Spiromastix* fungus (MCCC 3A00308) resulted in the isolation of eight compounds. Their structures were identified on the basis of the spectroscopic data. Compounds 1–8 are classified as depsidone-type (1–4), isocoumarin-type (5 and 6), and benzothiazole-type (7 and 8), of which 1–7 are new compounds and 1–3 along with 5 and 6 are chlorinated. Compound 3 is characterized by trichlorination and shows potent activities against Gram-positive pathogenic bacteria including *Staphylococcus aureus* ATCC 25923, *Bacillus thuringiensis* ATCC 10792, and *Bacillus subtilis* CMCC 63501, with minimum inhibitory concentration (MIC) values ranging from 0.5 to 1.0  $\mu\text{g mL}^{-1}$ . This study extends the chemical diversity of chlorinated natural products from marine-derived fungi and provides a promising lead for the development of antibacterial agents.

 Received 27th July 2021  
 Accepted 20th August 2021

DOI: 10.1039/d1ra05736g

[rsc.li/rsc-advances](http://rsc.li/rsc-advances)

## 1. Introduction

Marine-occurring halogenated compounds are widely distributed in macroorganisms (algae,<sup>1–3</sup> sponges,<sup>4–7</sup> corals,<sup>8,9</sup> and tunicates<sup>10,11</sup>) and microorganisms (fungi and bacteria)<sup>12–19</sup> that inhabit extreme marine environments. Halometabolites play a crucial role in pharmaceutical and agriculture applications. It is estimated that approximately 25% of clinically used medicines are halogenated, demonstrating a significant contribution of halogen atoms to bioactivity. Well-known halogenated medicines include the antibiotics chloramphenicol,<sup>20</sup> vancomycin,<sup>21</sup> and rebecamycin,<sup>22</sup> which are clinically used for their antibacterial and antitumor properties. Compared to those from marine macroorganisms, bioactive halometabolites from marine microorganisms are relatively unexplored. Nevertheless, a number of brominated and chlorinated resorcylics, *i.e.*, resorcylic acid lactones, with structural novelty have been isolated from marine-derived fungus.<sup>23</sup> In addition, marine-derived bacteria are a promising source for the production of halometabolites, as exemplified by the napyradiomycins obtained from a marine-derived actinomycete strain that show induction of apoptosis in the colon tumor cell line HCT-116,<sup>24</sup> and the chlorinated bisindole alkaloids (indimicins) obtained

from a deep-sea-derived *Streptomyces* sp. that show antitumor activities in cell levels.<sup>25</sup> Halogenated compounds in nature are catalyzed by the relevant halogenases, including haloperoxidases, nonheme Fe(II)- $\alpha$ -ketoglutarate-dependent halogenases, *S*-adenosyl-L-methionine-dependent halogenases and flavin-dependent halogenases to incorporate with fluorine, chlorine, bromine, and iodine donors.<sup>26,27</sup> In our previous study, a group of chlorodepsidones, namely, spiromastixones B–P, were obtained from a deep-sea *Spiromastix* sp. fungus; these compounds display selective activity against a panel of Gram-positive bacteria, including potent inhibition against methicillin-resistant and vancomycin-resistant pathogenic bacteria.<sup>14,28</sup> In addition to known chlorodepsidones, the LC-MS total ion chromatograph of the EtOAc extract of the fermented *Spiromastix* sp. strain provided the ion peaks for a number of unknown chlorinated compounds. To discover new chlorinated metabolites from the same fungal strain, the minor components from the EtOAc fraction of the solid cultures were subjected to chromatographic separation, resulting in the isolation of four new depsidones (spiromastixones P–S, 1–4), three new isocoumarins (spiromastimelleins A (5) and B (6)), and spiromastibenzothiazole A (7), together with the known benzothiazole 8,<sup>29</sup> of which 1–3 and 5 and 6 were chlorinated (Fig. 1). Herein, the structural elucidation and antibacterial activities of all compounds are described.

## 2. Experimental section

### 2.1 General procedure

UV spectra were recorded using a Cary 300 spectrometer. IR data were recorded using a Thermo Nicolet Nexus 470 FT-IR

<sup>a</sup>State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, 100191, P. R. China. E-mail: [whlin@bjmu.edu.cn](mailto:whlin@bjmu.edu.cn)

<sup>b</sup>Third Institute of Oceanography, SOA, Xiamen, 361005, P. R. China

<sup>c</sup>Institute of Ocean Research, Ningbo Institute of Marine Medicine, Peking University, Beijing, 100191, P. R. China

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d1ra05736g






Fig. 1 Chemical structures of 1–8.

spectrometer. A Bruker Avance-400 FT NMR spectrometer was used to measure NMR spectroscopic data, and DMSO-*d*<sub>6</sub> was used as the solvent with the reference peaks at  $\delta_{\text{H}}$  2.50 and  $\delta_{\text{C}}$  39.9 ppm. A Xevo G2 Q-TOF mass spectrometer was used to record the HRESIMS spectra. Semipreparative HPLC was performed using an Alltech instrument coupled with a YMC-packed reversed-phase C18 column (5  $\mu\text{m}$ , 10 mm  $\times$  250 mm). Column chromatography (CC) was carried out using silica gel (100–200 and 200–300 mesh), octadecyl silica (ODS, 50  $\mu\text{m}$ , YMC, Japan), and Sephadex LH-20 (18–110  $\mu\text{m}$ , Uppsala, Sweden). TLC analysis was performed using precoated silica gel plates (Merck, Kieselgel 60 F254). All solvents used for chromatography were of analytical grade.

## 2.2 Fungal material

The fungus *Spiromastix* sp. MCCC 3A00308 was isolated from South Atlantic Ocean sediment at a depth of 2869 m. The protocols for taxonomy and fermentation were described in the previous study.<sup>14</sup>

## 2.3 Isolation and purification

The fermented broth was extracted with EtOAc, and the EtOAc extract was fractionated into ten fractions (FA–FJ) using vacuum liquid chromatography on silica gel, with petroleum ether (PE)–acetone (50 : 1 to 1 : 1) as the eluent. Previously, fractions FF and FH have been chemically examined.<sup>14,28</sup> In this study, fraction FI was selected for further examination. FI (186.2 mg) was fractionated on a Sephadex LH-20 column eluted with MeOH to yield 4 (5.6 mg) and 1 (4.5 mg), along with subfractions FI5–FI8. FI5 (32.1 mg) was separated *via* semipreparative HPLC with MeCN–H<sub>2</sub>O (13 : 7) as the mobile phase to obtain 2 (2.3 mg) and 3 (3.8 mg). FI6 (56.5 mg) was purified *via* semipreparative HPLC using MeOH–H<sub>2</sub>O (7 : 3) as the mobile phase to yield 5 (8.5 mg) and 6 (7.3 mg). FI7 (26.6 mg) was separated *via* semipreparative HPLC with MeCN–H<sub>2</sub>O (3 : 17) to yield 7 (4.4 mg) and 8 (3.8 mg).

Spiromastixone P (1): white powder; UV (MeOH)  $\lambda_{\text{max}}$  (log  $\epsilon$ ) 225 (4.26), 262 (3.86) nm; IR (KBr)  $\nu_{\text{max}}$  3400, 2934, 1653, 1613, 1454, 1385, 1251  $\text{cm}^{-1}$ ; <sup>1</sup>H and <sup>13</sup>C NMR data, see Table 1; HRESIMS *m/z* 361.0843 [M – H]<sup>–</sup> (calcd for C<sub>19</sub>H<sub>18</sub>ClO<sub>5</sub>, 361.0843).

Spiromastixone Q (2): white powder; UV (MeOH)  $\lambda_{\text{max}}$  (log  $\epsilon$ ) 223 (4.32), 266 (3.63) nm; IR (KBr)  $\nu_{\text{max}}$  3391, 1726, 1595, 1431,

1241  $\text{cm}^{-1}$ ; <sup>1</sup>H and <sup>13</sup>C NMR data, see Table 1; HRESIMS *m/z* 395.0449 [M – H]<sup>–</sup> (calcd for C<sub>19</sub>H<sub>17</sub>Cl<sub>2</sub>O<sub>5</sub>, 395.0453).

Spiromastixone R (3): white powder; UV (MeOH)  $\lambda_{\text{max}}$  (log  $\epsilon$ ) 223 (4.25), 266 (3.71) nm; IR (KBr)  $\nu_{\text{max}}$  3381, 1729, 1594, 1428, 1240  $\text{cm}^{-1}$ ; <sup>1</sup>H and <sup>13</sup>C NMR data, see Table 1; HRESIMS *m/z* 429.0053 [M – H]<sup>–</sup> (calcd for C<sub>19</sub>H<sub>16</sub>Cl<sub>3</sub>O<sub>5</sub>, 429.0063).

Spiromastixone S (4): white powder; IR (KBr)  $\nu_{\text{max}}$  3259, 1718, 1607, 1451, 1251, 1221  $\text{cm}^{-1}$ ; <sup>1</sup>H and <sup>13</sup>C NMR data, see Table 1; HRESIMS *m/z* 371.1126 [M – H]<sup>–</sup> (calcd for C<sub>20</sub>H<sub>19</sub>O<sub>7</sub>, 371.1131).

Spiromastimellein A (5): colorless oil; [ $\alpha$ ]<sub>D</sub><sup>25</sup> + 223 (*c* 1.07, CH<sub>2</sub>Cl<sub>2</sub>); UV (MeOH)  $\lambda_{\text{max}}$  220 (3.15), 269 (2.65), 313 (1.74) nm; ECD (MeOH)  $\lambda_{\text{max}}$  ( $\Delta\epsilon$ ): 244 (+33.09), 264 (+36.11), 315 (–4.47) nm; IR (KBr)  $\nu_{\text{max}}$  3188, 1692, 1658, 1617, 1469, 1216  $\text{cm}^{-1}$ ; <sup>1</sup>H and <sup>13</sup>C NMR data, see Table 2; HRESIMS *m/z* 239.0118 [M – H]<sup>–</sup> (calcd for C<sub>11</sub>H<sub>8</sub>ClO<sub>4</sub>, 239.0111).

Spiromastimellein B (6): colorless oil; [ $\alpha$ ]<sub>D</sub><sup>25</sup> + 165 (*c* 0.65, CH<sub>2</sub>Cl<sub>2</sub>); UV (MeOH)  $\lambda_{\text{max}}$  218 (3.17), 269 (2.45), 313 (1.82) nm; ECD (MeOH)  $\lambda_{\text{max}}$  ( $\Delta\epsilon$ ): 245 (+24.15), 264 (+26.34), 318 (–2.48) nm; IR (KBr)  $\nu_{\text{max}}$  3419, 2962, 1767, 1710, 1690, 1663, 1461, 1243  $\text{cm}^{-1}$ ; <sup>1</sup>H and <sup>13</sup>C NMR data, see Table 2; HRESIMS *m/z* 272.9718 [M – H]<sup>–</sup> (calcd for C<sub>11</sub>H<sub>7</sub>Cl<sub>2</sub>O<sub>4</sub>, 272.9721).

Spiromastibenzothiazole A (7): colorless oil; UV (MeOH)  $\lambda_{\text{max}}$  220 (2.25), 240 (4.15), 273 (3.55) nm; <sup>1</sup>H and <sup>13</sup>C NMR data, see Table 2; HRESIMS *m/z* 208.0070 [M – H]<sup>–</sup> (calcd for C<sub>9</sub>H<sub>6</sub>NO<sub>3</sub>S, 208.0068).

## 2.4 Antibacterial test

Antibacterial effects against Gram-positive bacteria (*Staphylococcus aureus* ATCC 25923, *Bacillus thuringiensis* ATCC 10792, and *Bacillus subtilis* CMCC 63501) and a Gram-negative bacterium (*Escherichia coli* ATCC 25922) were detected using a protocol in the literature.<sup>28</sup> Chloroamphenicol was used as a positive control.

## 3. Results and discussion

Spiromastixone P (1) was obtained as a white powder. Its molecular formula was established as C<sub>19</sub>H<sub>19</sub>ClO<sub>5</sub> on the basis of the HRESIMS data (*m/z* 361.0843, [M – H]<sup>–</sup>), indicating ten degrees of unsaturation. The IR absorptions at 3400, 1653, and 1613  $\text{cm}^{-1}$  suggested the presence of hydroxy, carbonyl, and phenyl functionalities. The <sup>1</sup>H NMR data showed three



Table 1  $^1\text{H}$  and  $^{13}\text{C}$  NMR data of 1–4 in  $\text{DMSO}-d_6$ 

Position	1		2		3		4	
	$\delta_{\text{C}}$ , type	$\delta_{\text{H}}$ (J in Hz)	$\delta_{\text{C}}$ , type	$\delta_{\text{H}}$ (J in Hz)	$\delta_{\text{C}}$ , type	$\delta_{\text{H}}$ (J in Hz)	$\delta_{\text{C}}$ , type	$\delta_{\text{H}}$ (J in Hz)
1	111.4, C		119.5, C		119.9, C		111.5, C	
2	163.2, C		160.9, C		160.7, C		162.5, C	
3	105.1, CH	6.62, br s	105.9, CH	6.85, s	105.9, CH	6.88, s	105.1, CH	6.59, d (2.2)
4	162.7, C		158.5, C		158.7, C		163.2, C	
5	115.6, CH	6.63, br s	112.7, C		112.6, C		115.5, CH	6.62, d (2.2)
6	149.7, C		145.5, C		145.8, C		149.6, C	
7	162.6, C		161.9, C		161.3, C		162.8, C	
8	35.5, $\text{CH}_2$	2.67, t (7.5)	33.0, $\text{CH}_2$	2.83, t (7.4)	33.1, $\text{CH}_2$	2.83, t (7.5)	35.5, $\text{CH}_2$	2.68, t (7.5)
9	24.7, $\text{CH}_2$	1.49, m	22.7, $\text{CH}_2$	1.54, m	22.7, $\text{CH}_2$	1.54, m	24.7, $\text{CH}_2$	1.49, m
10	14.3, $\text{CH}_3$	0.85, t (7.2)	14.1, $\text{CH}_3$	0.86, t (7.4)	14.1, $\text{CH}_3$	0.86, t (7.3)	14.3, $\text{CH}_3$	0.85, t (7.3)
1'	141.6, C		142.2, C		142.6, C		141.2, C	
2'	143.1, C		145.5, C		140.4, C		145.3, C	
3'	105.7, CH	6.75, s	109.0, C		111.8, C		105.9, CH	6.61, s
4'	151.4, C		151.7, C		148.3, C		153.6, C	
5'	116.9, C		112.9, CH	6.69, s	119.2, C		119.7, C	
6'	134.1, C		133.5, C		132.1, C		134.0, C	
7'	29.9, $\text{CH}_2$	2.85, t (7.8)	31.2, $\text{CH}_2$	2.67, t (7.7)	29.9, $\text{CH}_2$	2.85, t (7.8)	29.8, $\text{CH}_2$	2.78, t (7.8)
8'	22.7, $\text{CH}_2$	1.54, m	23.6, $\text{CH}_2$	1.57, m	22.5, $\text{CH}_2$	1.56, m	24.3, $\text{CH}_2$	1.55, m
9'	14.6, $\text{CH}_3$	1.04, t (7.3)	14.3, $\text{CH}_3$	0.98, t (7.3)	14.5, $\text{CH}_3$	1.05, t (7.4)	14.8, $\text{CH}_3$	0.99, t (7.3)
10'							169.0, C	
4-OH		10.78, s		11.65, br s		11.75, br s		10.72, br s
4'-OH		10.53, s		10.50, s		10.45, br s		11.93, br s

aromatic protons, two methyl group triplets, four methylene groups, and two phenol protons (Table 1). Diagnostic  $^{13}\text{C}$  NMR and HSQC data revealed a total of 19 carbon resonances, from which 12 aromatic resonances for two phenyl groups, a carbonyl carbon at  $\delta_{\text{C}}$  162.6, four methylene and two methyl carbons were identified. These NMR data were characteristic of a depsidone, and closely resembled those of spiromastixone I,<sup>14</sup> a co-isolated analog from the same fungal strain. The 2D NMR data revealed

that the partial structure of ring A was identical to that of the known analog, but the absence of an aromatic proton and the presence of an additional quaternary carbon in aromatic ring C were recognized. The HMBC correlations from H-3' to C-1' ( $\delta_{\text{C}}$  141.6), C-2', C-4' ( $\delta_{\text{C}}$  151.4), and C-5' ( $\delta_{\text{C}}$  116.9), OH-4' ( $\delta_{\text{H}}$  10.53, s) to C-3' ( $\delta_{\text{C}}$  105.7), C-4', and C-5', and from H<sub>2</sub>-7' to C-1', C-5', and C-6' ( $\delta_{\text{C}}$  134.1), clarified that C-5' was chlorinated. An ether bond connecting rings A and C across C-2 to C-1' was evident

Table 2  $^1\text{H}$  and  $^{13}\text{C}$  NMR data of 5–8 in  $\text{DMSO}-d_6$ 

No.	5		6		7		8	
	$\delta_{\text{C}}$	$\delta_{\text{H}}$ (J in Hz)	$\delta_{\text{C}}$	$\delta_{\text{H}}$ (J in Hz)	$\delta_{\text{C}}$	$\delta_{\text{H}}$ (J in Hz)	$\delta_{\text{C}}$	$\delta_{\text{H}}$ (J in Hz)
1	164.8, C		165.3, C					
2					152.2 <sup>a</sup> , CH	9.06, s	152.4 <sup>a</sup> , CH	9.07, s
3	156.1, C		155.7, C					
3a					146.5, C		147.0, C	
4	35.0, CH	4.08, q (7.0)	34.8, CH	4.11, q (7.0)	130.9, C		125.2, CH	7.84, s
4a	142.8, C		140.3, C					
5	109.6, C		110.9, C		117.3, CH	6.92, d (2.3)	123.3, C	
6	161.3 <sup>a</sup> , C		157.5, C		155.9, C		154.6, C	
7	102.6, CH	6.49, s	108.3, C		105.8, CH	7.32, d (2.3)	106.3, CH	7.46, s
7a					7.32, d (2.3)		133.6, C	
8	161.9 <sup>a</sup> , C		157.8, C		37.7, $\text{CH}_2$	3.98, s	36.2, $\text{CH}_2$	3.62, s
8a	99.2, C		99.4, C					
9	97.2, $\text{CH}_2$	4.86, br s 4.80, br s	97.8, $\text{CH}_2$	4.90, d (1.8) 4.85, d (1.8)	172.7, C		173.0, C	
10	21.5, $\text{CH}_3$	1.34, d (7.0)	21.5, $\text{CH}_3$	1.36, d (7.0)				
6-OH		11.74, br s			9.78, s			10.0, s
8-OH		10.74, s		11.34, s				
COOH					12.32, br s			12.17, br s

<sup>a</sup> Assignment in the column can be interchanged.



from the NOE correlation between H-3 and H<sub>2</sub>-7' (Fig. 2). Thus, **1** was identified as a 5'-chlorinated spiromastixone I.

Spiromastixone Q (**2**) had a molecular formula of C<sub>19</sub>H<sub>18</sub>Cl<sub>2</sub>O<sub>5</sub> as determined by the HRESIMS data (*m/z* 395.0449 [M – H]<sup>–</sup>). A comparison of the NMR data (Table 1) revealed that **2** was an analog of spiromastixone K with the same partial structure of ring A. The difference was found in ring C, where a quaternary carbon was observed at C-3' (δ<sub>C</sub> 109.0) instead of the methine group of the known analogue. The HMBC correlations from 4'-OH (δ<sub>H</sub> 10.50, s) to C-3', C-4' (δ<sub>C</sub> 151.7), and C-5' (δ<sub>C</sub> 112.9), and from H-5' (δ<sub>H</sub> 6.69, s) to C-3', C-1' (δ<sub>C</sub> 142.2), and C-7' (δ<sub>C</sub> 31.2) suggested a chlorine substitution at C-3'. Thus, **2** was identified as a 3'-chlorinated spiromastixone K.<sup>14</sup>

The molecular formula of spiromastixone R (**3**) was determined as C<sub>19</sub>H<sub>17</sub>Cl<sub>3</sub>O<sub>5</sub> from the HRESIMS (*m/z* 429.0053, [M – H]<sup>–</sup>) and <sup>13</sup>C NMR data. The similar NMR data of **2** and **3**, except for the quaternary carbon at C-5' (δ<sub>C</sub> 119.2) for **3**, in association with the molecular composition identified **3** to be a 5'-chlorinated analog of **2**. The NOE interaction between H-3 (δ<sub>H</sub> 6.88) and H<sub>2</sub>-7' confirmed the location of the ether bond.

The HRESIMS data (*m/z* 371.1126 [M – H]<sup>–</sup>) indicated the molecular formula of spiromastixone S (**4**) to be C<sub>20</sub>H<sub>20</sub>O<sub>7</sub>. Its NMR data resembled those of spiromastixone I, but a carboxylic group (δ<sub>C</sub> 169.0) and the loss of H-5' were recognized. The HMBC correlations from H-3' (δ<sub>H</sub> 6.61) to C-1' (δ<sub>C</sub> 141.2) and C-5' (δ<sub>C</sub> 119.7) and from H<sub>2</sub>-7' (δ<sub>H</sub> 2.78) to C-1', C-5', and C-6' (δ<sub>C</sub> 134.0), along with the NOE interaction between H-3 (δ<sub>H</sub> 6.59) and H<sub>2</sub>-7', allowed the assignment of **4** as an analog of spiromastixone I with a carboxylic group at C-5'.

Spiromastimellein A (**5**) has a molecular formula of C<sub>11</sub>H<sub>9</sub>ClO<sub>4</sub> as determined from the HRESIMS and NMR data, requiring seven degrees of unsaturation and containing a chlorine atom. The IR absorptions at 3188 and 1658 cm<sup>–1</sup> suggested the presence of hydroxy and carbonyl functionalities. The <sup>1</sup>H NMR spectrum exhibited resonances including a methyl doublet, an exocyclic methylene group, an sp<sup>3</sup> methine, an aromatic singlet, and two D<sub>2</sub>O-exchangeable protons (Table 2). The <sup>13</sup>C NMR spectrum showed 11 carbon resonances, including six aromatic carbons corresponding to a phenyl unit, a carbonyl carbon, two olefinic carbons, an sp<sup>3</sup> methine, and a methyl carbon (Table 2). The aromatic proton H-7 (δ<sub>H</sub> 6.49, s) showed HMBC correlations with C-5 (δ<sub>C</sub> 117.3), C-6 (δ<sub>C</sub> 161.3), C-8 (δ<sub>C</sub> 161.9), and C-8a (δ<sub>C</sub> 99.2), which, in conjunction with the NOE relationships of H-7 with the phenol protons OH-6 (δ<sub>H</sub>

11.74, br) and OH-8 (δ<sub>H</sub> 10.74, s), indicated an aromatic ring with OH groups at C-6 and C-8. The long-range W correlation of H-7 with C-1 (δ<sub>C</sub> 164.8) suggested the presence of a carbonyl group at C-8a. The presence of a butene unit was established from the COSY relationship between H-4 (δ<sub>H</sub> 4.08, q) and H<sub>3</sub>-10 (δ<sub>H</sub> 1.34, d) together with the HMBC correlations between H<sub>2</sub>-9 (δ<sub>H</sub> 4.86, 4.80)/C-4 (δ<sub>C</sub> 35.0) and H<sub>3</sub>-10/C-3 (δ<sub>C</sub> 156.1). The linkage of the butane unit to C-4a (δ<sub>C</sub> 142.8) was deduced from the HMBC correlations between H<sub>3</sub>-10 and C-4a and from H-4 to C-4a, C-5 and C-8a. According to the molecular unsaturation, the one remaining unsaturation was contributed by the formation of a δ-lactone across C-1 and C-3, while a chlorine atom was substituted at C-5. Thus, **5** was determined to be a chlorinated isocoumarin with an exomethylene group at C-3.<sup>30</sup> Compound **5** and clearanol C<sup>30–32</sup> both possess a δ-lactone ring substituted with a methylene group at the C-3 position and a methyl group at the C-4 position. Since both compounds have similar optical rotations and ECD spectra ([α]<sub>D</sub><sup>25</sup> + 223 and positive Cotton Effects (CEs) at 244 and 264 nm for **5**; [α]<sub>D</sub><sup>25</sup> + 215.0 (MeOH) and positive CEs at 237 and 267 nm for clearanol C,<sup>30</sup> Fig. 3 and S8-2†), they are both assigned the absolute configuration of *S* at C-4.

The molecular formula of spiromastimellein B (**6**) was determined to be C<sub>11</sub>H<sub>8</sub>Cl<sub>2</sub>O<sub>4</sub> based on the HRESIMS and NMR data, containing two chlorine atoms. The NMR data of **6** (Table 2) were closely related to those of **5**, except that the aromatic carbon C-7 was substituted. The HMBC correlations of OH-8 (δ<sub>H</sub> 11.34) with the nonprotonated aromatic carbons C-7 (δ<sub>C</sub> 108.3), C-8 (δ<sub>C</sub> 157.8), and C-8a (δ<sub>C</sub> 99.4) supported the conclusion that **6** was a 7-chlorinated analog of **5**. The same sign of optical rotation and the similar ECD data (Fig. 3) suggested that both **5** and **6** had the same configuration.

Spiromastimellein C (**7**) has a molecular formula of C<sub>9</sub>H<sub>7</sub>NO<sub>3</sub>S as determined from the HRESIMS data (*m/z* 208.0070 [M – H]<sup>–</sup>), containing seven degrees of unsaturation. The <sup>1</sup>H NMR spectrum exhibited *meta*-coupled aromatic H-5 (δ<sub>H</sub> 6.92, d, *J* = 2.3 Hz) and H-7 protons (δ<sub>H</sub> 7.32, d, *J* = 2.3 Hz), an olefinic H-2 proton (δ<sub>H</sub> 9.06, s), methylene protons (δ<sub>H</sub> 3.98, s), and D<sub>2</sub>O-exchangeable OH-6 (δ<sub>H</sub> 9.78, s) and COOH protons (δ<sub>H</sub> 12.32, br) (Table 2). A *tetra*-substituted phenyl ring was established from the HMBC correlations from H-5 and H-7 to C-3a (δ<sub>C</sub> 146.5) and from OH-6 to C-5 (δ<sub>C</sub> 117.3), C-6 (δ<sub>C</sub> 155.9), and C-7 (δ<sub>C</sub> 105.8), indicating the presence of a phenolic group at C-6. The presence of an acetic acid unit at C-7 was evident from the HMBC




Fig. 2 Key COSY, HMBC and NOE correlations of **1**, **5** and **7**.






Fig. 3 Experimental ECD spectra of 5 and 6 in MeOH.

correlations from H<sub>2</sub>-8 to carboxylic carbon C-9 ( $\delta_{\text{C}}$  172.7) as well as to C-5 and C-3a. The remaining unit containing a nitrogen atom and a sulfur atom was suggested to be a thiazole moiety fused to the phenyl ring, which was supported by the HMBC correlations from H-2 to C-4a and C-8a.

In addition, a known compound identical to M4582 (**8**)<sup>30</sup> was isolated, which was identified as an analog of **7** with an alternative substitution of the acetic acid unit at C-5 on the basis of the NMR data.

Compounds **1–8** were tested for antibacterial activity against the Gram-positive bacterium strains *Staphylococcus aureus* ATCC 25923, *Bacillus thuringiensis* ATCC 10792, and *Bacillus subtilis* CMCC 63501, as well as against Gram-negative bacterium *Escherichia coli* ATCC 25922. Compounds **1–6** showed significant inhibitory activities against three Gram-positive bacteria with minimum inhibitory concentration (MIC) values ranging from 0.5–32  $\mu\text{g mL}^{-1}$ . However, all compounds exhibited weak activity against *E. coli*, implying selective inhibition toward Gram-positive bacteria (Table 3). Comparison of

the activities revealed that the capabilities of depsidones to produce antibacterial effects was related to the number of chlorine atoms in the backbone. Among them, **3**, which was trichlorinated, was the most active. Dichlorinated analogue **2** showed more activity than **1**; the latter incorporated one chlorine atom. Compound **4** without chlorine substitution showed weaker activity than **1–3**. Similarly, dichlorinated isocoumarin **6** showed more activity than the monochlorinated analogue **5**.

## 4. Conclusion

In summary, six new chlorinated metabolites were obtained from a deep-sea-derived *Spiromastix* sp. fungus. These findings enriched the chemical diversity of marine-fungus-derived chlorinated metabolites, and implied that marine-derived fungi are a potential source to discover halometabolites. The antibacterial activities of **3** were comparable to that of the positive control chloroamphenicol, suggesting that **3** was a promising lead for the development of an antibacterial agent.

Table 3 Antibacterial effects of **1–8**

Compound	MIC ( $\mu\text{g mL}^{-1}$ )			
	<i>Staphylococcus aureus</i> ATCC 25923	<i>Bacillus thuringiensis</i> ATCC 10792	<i>Bacillus subtilis</i> CMCC 63501	<i>Escherichia coli</i> ATCC 25922
<b>1</b>	8	4	8	>128
<b>2</b>	4	2	2	>128
<b>3</b>	1	1	0.5	>128
<b>4</b>	32	16	16	>128
<b>5</b>	32	32	16	>128
<b>6</b>	16	4	4	>128
<b>7</b>	>128	>128	>128	>128
<b>8</b>	>128	>128	>128	>128
CP <sup>a</sup>	1	1	1	4

<sup>a</sup> CP: chloroamphenicol used as a positive control.



The different scaffolds of **3** and chloroamphenicol implied that **3** may have a distinct mode of action, but this requires further investigation.

## Author contributions

SN and DL isolated all compounds; ZS and JH did the bioassay; AF and WL elucidated the structures and edited the article.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

This work was funded by DY135-B2-05, and the National Natural Science Foundation of China (81991525, 21861142006, 81872793, 81630089, 81803424).

## References

- G. W. Gribble, Naturally occurring organohalogen compounds—a comprehensive survey, *Prog. Chem. Org. Nat. Prod.*, 2010, **68**, 1–423.
- G. W. Gribble, Naturally occurring organohalogen compounds—a comprehensive update, *Prog. Chem. Org. Nat. Prod.*, 1996, **91**, 9–348.
- X. Yu, W. He, D. Liu, M. Feng, Y. Fang, B. Wang, L. Feng, Y. Guo and S. Mao, A *seco*-laurane sesquiterpene and related laurane derivatives from the red alga *Laurencia okamurai* Yamada, *Phytochemistry*, 2014, **103**, 162–170.
- L. Tian, Y. Feng, Y. Shimizu, T. A. Pfeifer, C. Wellington, J. N. A. Hooper and R. J. Quinn, ApoE secretion modulating bromotyrosine derivative from the Australian marine sponge *Callyspongia* sp., *Bioorg. Med. Chem. Lett.*, 2014, **24**, 3537–3540.
- T. Kusama, N. Tanaka, K. Sakai, T. Gono, J. Fromont, Y. Kashiwada and J. Kobayashi, Agelamadins A and B, dimeric bromopyrrole alkaloids from a marine sponge *Agelas* sp., *Org. Lett.*, 2014, **16**, 3916–3918.
- L. Tian, Y. Feng, Y. Shimizu, T. Pfeifer, C. Wellington, J. N. A. Hooper and R. J. Quinn, Aplysinellamides A–C, bromotyrosine-derived metabolites from an Australian *Aplysinella* sp. marine sponge, *J. Nat. Prod.*, 2014, **77**, 1210–1214.
- Y. Lee, W. Wang, H. Kim, A. G. Giri, D. H. Won, D. Hahn, K. R. Baek, J. Lee, I. Yang, H. Choi, J. Nam and H. Kang, Phorbaketals L–N, cytotoxic sesterterpenoids isolated from the marine sponge of the genus *Phorbas*, *Bioorg. Med. Chem. Lett.*, 2014, **24**, 4095–4098.
- Y. Su, C. Cheng, W. Chen, Y. Chang, Y. Chen, T. Hwang, Z. Wen, W. Wang, L. Fang, J. Chen, Y. Wu, J. Sheu and P. Sung, Briarenolide J, the first 12-chlorobriarane diterpenoid from an octocoral *Briareum* sp. (*Briareidae*), *Tetrahedron Lett.*, 2014, **55**, 6065–6067.
- H. Lei, J.-F. Sun, Z. Han, X.-F. Zhou, B. Yang and Y. Liu, Fragilisinins A–L, new briarane-type diterpenoids from gorgonian *Junceella fragilis*, *RSC Adv.*, 2014, **4**, 5261–5271.
- D. Smith, M. M. K. Kumar, H. Ramana and D. V. Rao, Rubrolide R: A new furanone metabolite from the ascidian *Synoicum* of the Indian Ocean, *Nat. Prod. Res.*, 2014, **28**, 12–17.
- M. Tadesse, J. Svenson, K. Sepčić, L. Trembleau, M. Engqvist, J. H. Andersen, M. Jaspars, K. Stensvåg and T. Haug, Isolation and synthesis of pulmonarins A and B, acetylcholinesterase inhibitors from the colonial ascidian *Synoicum pulmonaria*, *J. Nat. Prod.*, 2014, **77**, 364–369.
- W. Zhang, C. Shao, M. Chen, Q. Liu and C. Wang, Brominated resorcylic acid lactones from the marine-derived fungus *Cochliobolus lunatus* induced by histone deacetylase inhibitors, *Tetrahedron Lett.*, 2014, **55**, 4888–4891.
- T. El-Elimat, H. A. Raja, C. S. Day, W. Chen, S. M. Swanson and N. H. Oberlies, Greensporones: Resorcylic acid lactones from an aquatic *Halenospora* sp., *J. Nat. Prod.*, 2014, **77**, 2088–2098.
- S. Niu, D. Liu, X. Hu, P. Proksch, Z. Shao and W. Lin, Spiromastixones A–O, antibacterial chlorodepsidones from a deep-sea-derived *Spiromastix* sp. fungus, *J. Nat. Prod.*, 2014, **77**, 1021–1030.
- L. Farnæs, N. G. Coufal, C. A. Kauffman, A. L. Rheingold, A. G. DiPasquale, P. R. Jensen and W. Fenical, Napyradiomycin derivatives, produced by a marine-derived actinomycete, illustrate cytotoxicity by induction of apoptosis, *J. Nat. Prod.*, 2014, **77**, 15–21.
- W. Zhang, L. Ma, S. Li, Z. Liu, Y. Chen, H. Zhang, G. Zhang, Q. Zhang, X. Tian, C. Yuan, S. Zhang, W. Zhang and C. Zhang, Indimicins A–E, bisindole alkaloids from the deep-sea-derived *Streptomyces* sp. SCSIO 03032, *J. Nat. Prod.*, 2014, **77**, 1887–1892.
- M. Vegman and S. Carmeli, Three aeruginosins and a microviridin from a bloom assembly of *Microcystis* spp. collected from a fishpond near Kibbutz Lehavot HaBashan, Israel, *Tetrahedron*, 2014, **70**, 6817–6824.
- S. Luo, H. Kang, A. Krunić, G. E. Chlipala, G. Cai, W. Chen, S. G. Franzblau, S. M. Swanson and J. Orjala, Carbamidocyclophanes F and G with anti-*Mycobacterium tuberculosis* activity from the cultured freshwater cyanobacterium *Nostoc* sp., *Tetrahedron Lett.*, 2014, **55**, 686–689.
- M. E. F. Hegazy, A. Y. Moustfa, A. E. H. H. Mohamed, M. A. Alhammady, S. E. I. Elbehairi, S. Ohta and P. W. Pare, New cytotoxic halogenated sesquiterpenes from the Egyptian sea hare, *Aplysia oculifera*, *Tetrahedron Lett.*, 2014, **55**, 1711–1714.
- H. M. Feder Jr, Chloramphenicol: what we have learned in the last decade, *South. Med. J.*, 1986, **79**, 1129–1134.
- R. Álvarez, L. E. López Cortés, J. Molina, J. M. Cisneros and J. Pachón, Optimizing the clinical use of vancomycin, *Antimicrob. Agents Chemother.*, 2016, **60**, 2601–2609.
- J. A. Bush, B. H. Long, J. J. Catino, W. T. Bradner and K. Tomita, Production and biological activity of



- rebeccamycin, a novel antitumor agent, *J. Antibiot.*, 1987, **40**, 668–678.
- 23 W. Zhang, C. Shao, M. Chen, Q. Liu and C. Wang, Brominated resorcylic acid lactones from the marine-derived fungus *Cochliobolus lunatus* induced by histone deacetylase inhibitors, *Tetrahedron Lett.*, 2014, **55**, 4888–4891.
- 24 L. Farnaes, N. G. Coufal, C. A. Kauffman, A. L. Rheingold, A. G. DiPasquale, P. R. Jensen and W. Fenical, Napyradiomycin derivatives, produced by a marine-derived actinomycete, illustrate cytotoxicity by induction of apoptosis, *J. Nat. Prod.*, 2014, **77**, 15–21.
- 25 K. A. McArthur, S. S. Mitchell, G. Tsueng, A. Rheingold, D. J. White, J. Grodberg, K. S. Lam and B. C. M. Potts, Lynamycins A–E, chlorinated bisindole pyrrole antibiotics from a novel marine actinomycete, *J. Nat. Prod.*, 2008, **71**, 1732–1737.
- 26 J. Zeng and J. Zhan, Chlorinated natural products and related halogenases, *Isr. J. Chem.*, 2019, **59**, 387–402.
- 27 A. S. Eustáquio, F. Pojer, J. P. Noel and B. S. Moore, Discovery and characterization of a marine bacterial SAM-dependent chlorinase, *Nat. Chem. Biol.*, 2008, **4**, 69–74.
- 28 S. Niu, D. Liu, P. Proksch, Z. Shao and W. Lin, New polyphenols from a deep sea *Spiromastix* sp. fungus, and their antibacterial activities, *Mar. Drugs*, 2015, **13**, 2526–2540.
- 29 M. D. Parenti, S. Pacchioni, A. M. Ferrari and G. Rastelli, Three-dimensional quantitative structure–activity relationship analysis of a set of *Plasmodium falciparum* dihydrofolate reductase inhibitors using a pharmacophore generation approach, *J. Med. Chem.*, 2004, **47**, 4258–4267.
- 30 W. C. Tayone, S. Kanamaru, M. Honma, K. Tanaka, T. Nehira and M. Hashimoto, Absolute stereochemistry of novel isochromanone derivatives from *Leptosphaeria* sp. KTC 727, *Biosci., Biotechnol., Biochem.*, 2011, **75**, 2390–2393.
- 31 T. El-Elimat, H. A. Raja, M. Figueroa, J. O. Falkinham and N. H. Oberlies, Isochromenones, isobenzofuranone, and tetrahydronaphthalenes produced by *Paraphoma radicina*, a fungus isolated from a freshwater habitat, *Phytochemistry*, 2014, **104**, 114–120.
- 32 J. Tang, W. Wang, A. Li, B. Yan, R. Chen, X. Li, X. Du, H. Sun and J. Pu, Polyketides from the endophytic fungus *Phomopsis* sp. sh917 by using the one strain/many compounds strategy, *Tetrahedron*, 2017, **73**, 3577–3584.

